Giuseppe Salfi

Bellinzona, TI, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.

Journal: Drugs

Published: April 16, 2026

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

Journal: European urology

Published: March 23, 2026

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

Journal: European urology oncology

Published: February 20, 2026

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Journal: Prostate cancer and prostatic diseases

Published: January 03, 2026

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.

Journal: European urology oncology

Published: November 11, 2025

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Journal: Cancers

Published: October 16, 2025

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Journal: Prostate cancer and prostatic diseases

Published: September 04, 2025

When suboptimal post-protocol care in oncology trials is rewarded.

When suboptimal post-protocol care in oncology trials is rewarded.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 22, 2025

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Journal: Frontiers in oncology

Published: June 16, 2025

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting.

Journal: International journal of molecular sciences

Published: April 22, 2025

The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.

Journal: International journal of molecular sciences

Published: December 03, 2024

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.

Journal: European urology open science

Published: October 31, 2024

Showing 1-12 of 18

Last Updated: 09/26/2026